Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide

L. Agertoft, F.E. Larsen, S. Pedersen

ABSTRACT: We assessed the effect of long-term treatment with inhaled budesonide (BUD) on the occurrence of posterior subcapsular cataracts (PSC), bruises and hoarseness in children with asthma.

Slit lamp examinations were performed in 157 asthmatic children treated with inhaled BUD at a mean daily dose of 504 µg (range 189–1,322 µg) for 3–6 yrs (mean 4.4 yrs). Measurements were compared with 111 age-matched children with asthma, who had never received treatment of exogenous corticosteroids (control group). The children were examined for bruises, their tendency to bruise and occurrence of voice changes.

No incidents of PSC ascribable to BUD treatment were seen. One patient in the BUD group had been diagnosed with PSC before the study and this was still present. There were no statistically significant differences in number of bruises between the two groups (BUD=3.3, controls=3.2; p=0.70), area covered by bruises (BUD=10 cm², controls=10.1 cm²; p=0.97), tendency to bruise (BUD=5/10, controls=5/10) or occurrence of hoarseness (BUD=20%, controls=21%; p=0.92). Furthermore, there was no correlation between the occurrence of bruises or tendency to bruise and duration of treatment, accumulated or current dose of BUD.

A 3–6 yr treatment of children with inhaled budesonide at an average daily dose of about 500 µg is not associated with an increased occurrence of posterior subcapsular cataract, bruises, tendency to bruise, hoarseness or other noticeable voice changes.

Advances in our understanding of the pathophysiology of asthma as an inflammatory disease, even in patients with mild illness, have resulted in the early use of inhaled corticosteroids for optimal treatment of both adults and children [1–3]. Several controlled clinical trials have established the efficacy of inhaled corticosteroids in improving virtually all outcome measures in asthma to a greater extent than any other antiasthma drug [2, 4]. This change in therapy has occurred more rapidly in the adult asthmatic population than in the paediatric, mainly because paediatricians (and parents) are still concerned about the potential adverse effects of long-term treatment with inhaled corticosteroids in growing children.

Systemic corticosteroids have been shown to be associated with an increased occurrence of cataracts and bruises in children and adults [5–8]. Moreover, long-term, high-dose inhaled corticosteroid therapy in adults has been associated with dermal thinning and increased occurrence of bruises and hoarseness [9–11]. At present, our knowledge is rather sparse about the occurrence of posterior subcapsular cataracts (PSC), bruises and hoarseness in children with asthma receiving continuous long-term treatment with inhaled corticosteroids.

Several studies have evaluated the influence of inhaled corticosteroids on markers of collagen formation and degradation [12–15]. Generally, the results from these studies have been reassuring: doses of inhaled corticosteroids producing optimal disease control in the majority of patients are not associated with any detectable effect on these markers, although significant changes have sometimes been reported with high-dose therapy. It remains to be established, however, whether these small changes in markers of collagen formation and degradation are clinically important.

The aim of the present study was to assess the occurrence of PSCs, bruises and hoarseness in children with asthma treated for at least 3 yrs with the inhaled corticosteroid budesonide, and to compare the findings with those of asthmatic children who had never received continuous treatment with exogenous corticosteroids.

Patients and methods

Children with persistent asthma and no other chronic disease were studied. The patients were well-known to our
The occurrence of PSCs, bruises and hoarseness. To avoid the confounding influence of systemic corticosteroids, the following exclusion criteria were used in the present study: >14 days treatment with systemic corticosteroids ever (both groups of children); inhaled corticosteroids for >2 weeks ever (control group); topical (skin) corticosteroids after the age of 2 yrs ever applied to >25% of the body surface (both groups); metabolic diseases, such as diabetes (both groups); family history PSC; and use of nasal corticosteroids, except for the treatment of seasonal rhinitis <1 month yr⁻¹ (both groups).

All patients were questioned about the occurrence of any incidents (trauma) in the past that might cause opacities of the lens.

**Cataract assessment**

A narrow-beam slit lamp examination was performed in all patients after dilation of the pupils. All examinations were carried out by the same experienced, specialist-certified ophthalmologist, who had no knowledge of the treatment received by the children. Opacities, if present, were classified as PSC or non-PSC opacities. The latter included various lesions not related to corticosteroid therapy, such as nuclear sclerosis or congenital cataracts.

**Bruises**

The number and size of bruises on one forearm and one lower leg were recorded. The physical examinations were always done on the limbs of the dominant-hand side of the patient. Additionally, each family was asked to rate, using a visual analogue scale (0–10), their child’s tendency to bruise (0=not at all, 10=very easily).

Since differences in physical activity between the two groups might influence the occurrence of bruises, an assessment of each patient’s physical activity was made with the aid of a visual analogue scale and a standardized questionnaire about daily activities, including participation in sports (number of times per week). The visual analogue scale (0–10) scored the children’s participation in play and daily physical activities within the previous month (0=none at all, 10=very high level).

**Hoarseness**

All families were asked if their child experienced hoarseness or other noticeable voice changes. The answer options were: "Yes", "No" or "Don’t know". The recordings of bruises and hoarseness were always done by a person who had no knowledge of the treatment received by the children.

The study was approved by the local ethics committee and all families had given verbal and written informed consent to participation.

**Statistical analysis**

Fisher’s exact test (one-sided) was used to assess whether the PSC was more frequent in the budesonide group than in the control group. All answers provided by the families to the questions asked during the study were...
compared between groups using chi-square tests for homogeneity. The number and size of bruises in the two groups were compared by t-tests.

The relationship between bruises and the accumulated dose and total duration of treatment with budesonide was assessed only through scatter plots.

**Results**

A total of 268 children were studied: 157 in the budesonide group and 111 in the control group. The patients characteristics are shown in Table 1. The two groups were comparable with respect to age, height and weight. The proportion of males was somewhat higher, and the mean duration of asthma at the time of the study was significantly longer in the budesonide group than in the control group. Furthermore, children treated with budesonide had a higher forced expiratory volume in one second (FEV1) (% predicted) than the children in the control group.

Eight percent of the children in the budesonide group used inhaled long-acting β₂-agonists, and 2% used theophylline. In the control group, 15% used inhaled long-acting β₂-agonists, 22% used theophylline, 20% used sodium cromoglycate and 1% used oral β₂-agonists. All children in both groups used inhaled β₂-agonists as needed. The mean compliance with inhaled budesonide was assessed to be 78% (range 42–110%).

The mean total accumulated dose of budesonide for children in the budesonide group was 813.1 mg (range 249–2,800 mg), and the mean treatment duration was 1,603 days (4.4 yrs) (range: 3–6 yrs), giving a mean average daily dose of 504 µg (range: 189–1,322 µg).

**Cataracts**

Slit lamp examinations were not performed in six patients (two in the budesonide group and four in the control group) because the patients never visited the ophthalmologist despite repeated invitations. One patient in the budesonide group had a PSC (one eye only) that had already been diagnosed by another ophthalmologist 2 yrs prior to initiation of budesonide treatment. No other incidents of PSC were found in the two groups. Fisher’s exact test did not find any increased risk of PSC in the budesonide group when compared with the control group (p=0.46). Three children were diagnosed with non-PSC opacities; two children in the budesonide group showed signs consistent with congenital unilateral cataract and one child in the control group showed signs consistent with congenital bilateral cataract.

Table 1. – Patient characteristics of the two groups of children with asthma

<table>
<thead>
<tr>
<th>Number</th>
<th>Control group</th>
<th>Budesonide group</th>
</tr>
</thead>
<tbody>
<tr>
<td>% M/% F</td>
<td>55/45</td>
<td>69/31</td>
</tr>
<tr>
<td>Age yrs</td>
<td>9.9 (5–16)</td>
<td>10.3 (5–16)</td>
</tr>
<tr>
<td>Height kg</td>
<td>142 (107–177)</td>
<td>143 (104–182)</td>
</tr>
<tr>
<td>Weight kg</td>
<td>37.4 (16–75)</td>
<td>38.1 (16–90)</td>
</tr>
<tr>
<td>Asthma duration yrs</td>
<td>4.5 (0.5–12)</td>
<td>8.3 (4–16)</td>
</tr>
<tr>
<td>FEV1 % pred</td>
<td>81 (60–97)</td>
<td>97 (76–106)</td>
</tr>
</tbody>
</table>

Data are presented as mean values and ranges. FEV1: forced expiratory volume in one second; M: males; F: females.

Twenty-five per cent of the children in both groups reported previous events (physical trauma of the eye) that might influence the occurrence of lens opacities.

**Bruises**

There were no statistically significant differences in the number of bruises between the two groups (BUD=3.3, controls=3.2; p=0.70), area on arm and leg covered by bruises (BUD=10 cm², controls=10.1 cm²; p=0.97), tendency to bruise as assessed using a visual analogue scale (BUD=5/10, controls=5/10; p=0.98) or by the answer to the question: "Does your child bruise easily?" (table 2). Furthermore, there was no correlation between the occurrence of bruises or tendency to bruise and duration of treatment, accumulated, or current dose of budesonide (fig. 1).

Table 2. – Answers to the question “Does your child bruise easily?”

<table>
<thead>
<tr>
<th></th>
<th>No</th>
<th>Yes</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budesonide (n=157)</td>
<td>75 (68)</td>
<td>35 (31)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Control group (n=111)</td>
<td>75 (68)</td>
<td>35 (31)</td>
<td>4 (1)</td>
</tr>
</tbody>
</table>

Data presented as number of children and percentages in parenthesis. There was no statistically significant difference between the two groups (p=0.14).

![Figure 1](image-url)  
Fig. 1. – Total number of bruises as a function of accumulated dose and time on inhaled budesonide. No correlation was seen between the occurrence of bruises or tendency to bruise and duration of treatment, accumulated, or current dose of budesonide. Solid line: geometric mean.
The number of times per week that the children participated in sports activities was the same in both groups (1.46 (BUD) and 1.40 (control), respectively). However, based upon the results from the visual analogue scale, the children in the budesonide group were more physically active than the children in the control group (spent more hours outside playing, biked or walked to school more frequently, etc.), the mean scores in the two groups being 8.3 (BUD) and 5.7 (control) (p<0.01).

**Hoarseness**

There was no statistically significant difference between the two groups in occurrence of hoarseness or other noticeable voice changes. This was reported in 20% in the budesonide group and 21% in the control group (table 3).

**Discussion**

The cataracts that complicate chronic systemic corticosteroid therapy are typically of the PSC type, although nuclear lesions may be seen as well [8, 16]. The prevalence has been reported to be influenced by the daily and cumulative dose of corticosteroid and duration of treatment and probably also by patient age [5]. Furthermore, some researchers have suggested individual patient susceptibility as an important factor [17].

When designing the present study, we tried to avoid some of the problems of interpreting potential findings of opacities in the budesonide-treated children. This was achieved by restricting the study to well-characterized patients who had never received systemic corticosteroids for >14 days, and by including a control group of children with asthma who had never received exogenous corticosteroids. This is clinically more relevant than a comparison with healthy children because cataracts may occur at a higher frequency in atopic patients in the anterior subcapsule, the posterior subcapsule or throughout the lenses [18–20]. In addition, the ophthalmologist was blinded with respect to the treatment given in order to minimize any possible bias. The only case of an earlier-diagnosed lens opacity was also detected during the study, indirectly supporting the quality of the slit lamp examination. It was not possible, however, to assess accurately whether the opacity in the posterior subcapsular region had progressed since the initial diagnosis, but it appeared not to be the case.

The pathogenesis of corticosteroid-induced PSC is not fully understood. Disturbances of carbohydrate metabolism have been suggested to play an important role. It is known that budesonide, given in the doses used in the present study, does not exert any major adverse influence on carbohydrate metabolism in children [21, 22]. Hence, if the theory about disturbed carbohydrate metabolism is accurate, we would not expect to find any PSC in the budesonide-treated group. This, indeed, was what we found. This finding corroborates with those reported in previously published studies of smaller groups of less well-characterized children, adolescent and adult patients treated for shorter periods of time with inhaled glucocorticosteroids [5, 17–25]. These data strongly suggest that long-term treatment with budesonide in the doses used in the present study is unlikely to cause PSC formation. Furthermore, routine ophthalmological surveillance for PSC in children receiving long-term inhaled corticosteroid treatment is not warranted and probably not cost-effective.

The budesonide group differed from the control group with respect to duration of asthma at the time of study and to the proportion of males and females. These variables did not influence the parameters studied, so it is unlikely that these intergroup differences influenced the results.

To the best of our knowledge, the influence of inhaled corticosteroids on the occurrence of bruises has not previously been studied in children. High doses given for several years have been reported to increase bruising in adults, especially postmenopausal females. In these patients, there seems to be a correlation between bruises and the duration of treatment and accumulated dose [9, 10]. In the present study, there was no difference in the occurrence of bruises or tendency to bruise between the two groups, despite the fact that the children in the budesonide group were more physically active than the children in the control group, a factor that would logically cause one to expect an increased number of bruises. Moreover, neither accumulated nor current budesonide dose, nor duration of treatment correlated with the occurrence of bruising. This strongly suggests that bruising is unlikely to be a problem in children receiving long-term treatment with inhaled corticosteroids in the doses used in the present study. This is in accordance with the findings of studies evaluating the influence of inhaled corticosteroids on markers of collagen formation and degradation in children [12–15]. Only high doses of inhaled corticosteroids seem to be associated with subtle changes in some of these markers, suggesting a reduced collagen turnover rate. It remains to be established, however, whether these short-term changes in markers of collagen formation and degradation are clinically important. The present findings suggest that they are not.

Bruising may be a relatively crude outcome measure. Ultrasound has recently been suggested as a useful tool in detecting subtle changes in the composition and texture of the skin caused by exogenous corticosteroids [26], but further studies are required to confirm the accuracy and clinical value of ultrasound for this purpose.

The frequency of hoarseness of around 20% in the budesonide group is in agreement with the findings of many studies in mainly adult patients [11, 27–32]. Hoarseness is normally assumed to be the most frequent adverse effect of inhaled corticosteroid treatment. Therefore, the absence of an increased occurrence in the budesonide group was very surprising. The interesting finding in this study was that the rate did not differ from the control group, emphasizing the importance of including a control group for comparison and perhaps also blinding the study.

<table>
<thead>
<tr>
<th></th>
<th>No</th>
<th>Yes</th>
<th>Don’t know</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budesonide (n=157)</td>
<td>121 (77)</td>
<td>31 (20)</td>
<td>5 (3)</td>
</tr>
<tr>
<td>Control group (n=111)</td>
<td>87 (78)</td>
<td>23 (21)</td>
<td>1 (1)</td>
</tr>
</tbody>
</table>

Data presented as number of children and percentages in parenthesis. There was no statistically significant difference between the two groups (p=0.92).
to avoid bias. These precautions have not always been taken in other studies.

The lack of an increased occurrence of hoarseness in the budesonide group might be due to inaccurate or imprecise questioning of the patients. However, the questions that we posed to the families were quite similar to those used in other studies, so we do not have reason to believe that this caused the discrepancy. It may be that the inhalation device used in this investigation, the dry powder inhaler Turbuhaler®, might have had a positive influence on hoarseness. Reports in the literature suggest that this device may reduce the occurrence of hoarseness as compared with a pMDI [27, 33], probably because the vocal cords are in a more open position when inhaling against a certain resistance [34, 35]. The majority of reports on hoarseness have been in adults, who have been assessed rather early after initiation of treatment with inhaled corticosteroids. It is not known whether children and adults differ with respect to susceptibility to this possible adverse effect or whether voice changes are more frequent at the beginning of the treatment. Finally, the children in our study had received the therapy for several years and therefore may have become used to any possible voice changes.

It would have been desirable to have electronic monitoring of compliance to accurately assess the actual dose taken. That was not possible, mainly because we could not obtain a Turbuhaler with an electronic recording of the number of doses taken. Therefore, we had to monitor compliance in a less accurate way. However, during a 1 yr period, we were able to electronically monitor the actual number of doses taken in some of the patients. These measures were in reasonably good agreement with our other recordings (the mean compliance was the same). This suggests that our compliance estimate was fairly accurate. This assumption is indirectly supported by the excellent clinical results seen in the budesonide group [1].

Conclusion

We conclude that three to six years’ treatment of children with inhaled budesonide at an average daily dose of about 500 µg is not associated with an increased occurrence of posterior subcapsular cataracts, bruises, tendency to bruise, hoarseness or noticeable voice changes in children with chronic asthma.

References